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Abstract 
Context: Sarcopenic obesity (SO), a combination of excess weight and reduced muscle mass 
and/or strength, is suggested to be associated with an increased risk of adverse health outcomes. 
Objectives: To examine the prevalence and characteristics of Sarcopenic and SO defined by 
using different indices such as Appendicular Skeletal muscle Mass (ASM)/height2 and Skeletal 
Muscle Index (SMI (%): skeletal muscle mass (kg)/weight (kg) × 100) for Korean adults.  
Methods: 591 participants were recruited from the Korean Sarcopenic Obesity Study (KSOS) 
which is an ongoing prospective observational cohort study. Analysis was conducted in 526 
participants (328 women, 198 men) who had complete data on body composition using Dual X-
ray absorptiometry and computed tomography.  
Results: The prevalence of sarcopenia and SO increases with aging. Using two or more 
standard deviations (SD) of ASM/height2 below reference values from young, healthy adults as 
a definition of sarcopenia, the prevalence of sarcopenia and SO was 6.3% and 1.3% in men and 
4.1% and 1.7% in women over 60 years of age. However, using two or more SD of SMI, the 
prevalence of sarcopenia and SO was 5.1% and 5.1% respectively in men and 14.2% and 12.5% 
respectively in women. As defined by SMI, subjects with SO had 3 times the risk of metabolic 
syndrome (OR = 3.03, 95% confidence interval (CI) = 1.26-7.26) and subjects with non-
sarcopenic obesity had approximately 2 times the risk of metabolic syndrome (OR = 1.89, 95% 
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CI = 1.18-3.02) compared with normal subjects.  
Conclusion: Obese subjects with relative sarcopenia were associated with a greater likelihood 
for metabolic syndrome. As Koreans were more obese and aging, the prevalence of SO and its 
impact on health outcomes are estimated to be rapidly grow. Further research is requested to 
establish the definition, cause and consequences of SO. 
 
Keywords: Skeletal muscle, Aging, Obesity, Sarcopenia, Prevalence, Metabolic syndrome 
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Introduction  
The epidemiological trends that represent our generation are the obesity epidemic and the 
aging of the population (1). Aging promotes a progressive loss of muscle mass and strength 
called sarcopenia from Greek for ‘poverty of flesh’ (2). Sarcopenia leads to functional 
impairment and physical disability (3). Moreover, aging and physical disability due to 
sarcopenia are also related with an increase in visceral obesity which is an important factor in 
the development of metabolic syndrome and cardiovascular disease (4). Therefore, sarcopenia 
and visceral obesity in the elderly may synergistically increase their effect on physical disability, 
metabolic disorders, cardiovascular disease and mortality (5). Combination of excess body fat 
and reduced muscle mass and/or strength with aging was recently defined as sarcopenic obesity 
(SO). Surplus energy intake, physical inactivity, low-grade inflammation and changes of 
hormones such as growth hormone and testosterone may be all related to the development of SO 
(5). Since the obese elderly population is continuously increasing, the impact of SO is estimated 
to be dramatic in the next decade (2).  
Korea is rapidly becoming a society with an elderly population as in other developed 
countries. According to Korea National Statistical Office, 7.2% of the Korean population was 
aged 65 and older (percentage of elderly) in 2000. The percentage is expected to rise to 19.1% 
in 2025, and 34.4% in 2050 (6). The speed at which Korea is becoming an older, aged society is 
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unprecedented among the other OECD countries. Therefore, the research of SO is essential for 
the development of public health programs for the elderly Korean population. 
Several definitions of sarcopenia and SO have already been proposed in western countries. 
Baumgartner et al. defined sarcopenia as reduction in appendicular skeletal muscle mass (ASM) 
divided by height squared (ASM/height2) of two standard deviations or more below the normal 
means for younger reference group measured using Dual X-ray Absorptiometry (DXA). They 
reported that the prevalence of SO was 4.4% in men and 3.0% in women over 60 years of age in 
the New Mexico Aging Process Study (7). In community-dwelling elderly women in Verona, 
Zoico et al. reported that the prevalence of SO was 12.4% defining SO as the two lower 
quintiles of muscle mass plus two higher quintiles of fat mass (8). Using the same definition, 
Davison et al. reported that the prevalence of SO was 9.6% in men and 7.4% in women from the 
bioelectrical impedance analysis (BIA) data of NHANES III (9). In addition, Janssen et al. 
proposed the definition of sarcopenia as skeletal muscle index (SMI (%); skeletal muscle mass 
(kg)/weight (kg) × 100) of one or two standard deviations below the mean for the younger 
reference group although they did not examine the prevalence of SO (3). Recently, Newman et 
al. proposed the new criteria for sarcopenia based on the amount of lean mass being lower than 
expected for a given amount of fat mass using residuals from linear regression models (10). In 
most of previous studies for SO, obesity was defined as the two highest quintiles of total body 
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fat mass obtained using DXA (8, 9). The prevalence of SO may vary depending on the criteria, 
reference populations and definition used. 
In spite of the growing importance of SO, only a few studies evaluating the definition and 
prevalence of SO was performed in Caucasian populations and there have been no previous 
studies in non-Caucasian populations. Furthermore, there was very scanty report about 
relationship between SO and metabolic disorders. Therefore, we examined the prevalence of 
sarcopenia and SO using different definitions in Korean adults. In addition, according to SO as 
defined by different indices such as ASM/height2 and SMI, we compared the anthropometric 
and metabolic parameters, and explored the association between SO and metabolic syndrome. 
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Materials and methods 
Subjects 
This study is part of the Korean SO Study (KSOS) which is an ongoing epidemiologic study 
supported by Korea Science and Engineering Foundation (KOSEF). This is a prospective 
observational cohort study enrolled between September 2007 and August 2008, and a total of 
591 healthy volunteers aged 20-88 years old were recruited from residents in Seoul, Korea. The 
KSOS was planned to examine the prevalence of SO in Korean adults and to evaluate the effect 
of SO on metabolic disorders and likely health outcomes. All participants were apparently 
healthy and had no history of cardiovascular disease (myocardial infarction, unstable angina, 
stroke or cardiovascular revascularization), any type of diabetes, stage 2 hypertension (resting 
blood pressure, ≥160/100 mmHg), malignant disease or severe renal or hepatic disease. 
Subjects taking medications that might affect body weight or body composition were excluded. 
Analysis was conducted on 526 participants (328 women, 198 men) who had complete data on 
body composition. Among them, young healthy volunteers (aged 20-40; 145 subjects; 54 men, 
91 women) were considered as the sex-specific young reference group. All participants 
provided written informed consent and the Korea University Institutional Review Board, in 
accordance with the Declaration of Helsinki of the World Medical Association, approved this 
study protocol. 
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Anthropometric and laboratory measurements  
BMI was calculated as weight in kilograms divided by the square of the height in meters. 
Waist circumference was measured at the midpoint between the lower border of the rib cage and 
iliac crest. All blood samples were obtained in the morning after a 12-hour overnight fast, and 
were immediately stored at -80 °C for subsequent assays. Serum triglycerides and HDL 
cholesterol were determined enzymatically using a chemistry analyzer (Hitachi 747; Tokyo, 
Japan). A glucose oxidase method was used to measure plasma glucose. 
 
Definition of metabolic syndrome  
Metabolic syndrome was defined based on the National Cholesterol Education Program’s 
ATP-III (11) definition. In the present study, we used the definition of abdominal obesity 
recommended by the WHO Western Pacific Region which is a waist circumference ≥90 cm in 
males and ≥80 cm in females.  
 
Computed tomography  
Abdominal visceral fat area (VFA), subcutaneous fat area (SFA) and mid-thigh muscle area 
(MTMA) were measured with computed tomography (CT) scans (Brilliance 64, Philips Medical 
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Systems; Cleveland, Ohio). With the subject in the supine position, a 3-mm CT slice scan was 
acquired at the L4 to L5 level to measure VFA and total abdominal fat area (TFA). Cross-
sectional surface area (in cm2) of different abdominal fat compartments was calculated at this 
slice using a commercially available CT software (Rapidia 2.8; INFINITT, Seoul, Korea), 
which determined adipose tissue area electronically by setting the attenuation values for a 
region of interest within a range of -190 to -30 Hounsfield units. VFA was quantified by 
determining the intra-abdominal cavity at the internal aspect of the abdominal and oblique 
muscle walls surrounding the cavity and the posterior aspect of the vertebral body. SFA was 
calculated by subtracting VFA from TFA. A cross-sectional scan of the same thickness was 
obtained for the left thigh halfway between the pubic symphysis and the inferior condyle of the 
femur as described previously and skeletal muscle areas fell within a range of 0 to 100 HU (12). 
VFA to MTMA ratio (VMR) were calculated by dividing the VFA by MTMA respectively (13). 
 
Dual-energy x-ray absorptiometry and bioelectrical impedance analysis 
A Whole body DXA scan was performed to measure total and regional lean mass (kg) and 
total body fat (kg) and total body fat percentage (%) using fan-beam technology (Hologic 
Discovery A, Hologic; Bedford, MA, USA). ASM was calculated as the sum of skeletal muscle 
in arms and legs (14). Total skeletal muscle mass (kg) was obtained from ASM by using the 
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predictive equation of Kim et al (15). SMI (%) was obtained by the total skeletal muscle mass 
adjusted by weight as described by Janssen et al (3). Bioelectrical impedance analysis using the 
Inbody 3.0 (Biospace, Seoul, Korea) was used to estimate total body water and free fat mass 
(FFM) by measuring the resistance of the body to a small alternating electric current.  
 
Definitions of sarcopenia and sarcopenic obesity 
First, sarcopenia was defined as the ASM/height2 less than two standard deviations (SD) 
below the sex-specific normal mean for younger reference group (7) or the two lower quintile in 
all of the study population (8, 9). Alternatively, sarcopenia was defined as the SMI of two 
standard deviations below the sex-specific mean value for young reference group from the 
entire study population (3). Lastly, residual method was defined as the reference values the sex-
specific lower 20% of the distribution of residuals between measured ASM and ASM which is 
predicted by linear regression analysis used to model the relationship between ASM as a 
dependent variable, and age, height (meters) and total fat mass (kg) as the independent variables 
(10). A positive residual means a relatively muscular individual, whereas negative residual is 
indicative of a relatively sarcopenic individual (16).  
Obesity was defined as values greater than the median total fat percentage for each sex (7) or 
the upper two quintiles for total body fat percentage of the study population (8, 9). SO was 
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defined as high total body fat percentage plus low relative skeletal muscle mass in the same 
subjects according to other previous studies (7-9). We classified four sarcopenia/obesity groups 
using the criteria that SMI of 2SD below the value of the young reference group plus upper two 
quintiles for total body fat percentage. The four groups included normal body fat and muscle 
mass, sarcopenia (and normal body fat), obesity (and normal muscle mass) and SO. 
 
Statistical analysis  
Data are expressed as the mean ± SD or median and inter-quartile range (25%-75%) or as 
percentage. Differences between groups were tested using a Student t-test or the Mann-Whitney 
U test, and the Chi-square test was used to test for differences in the distribution of categorical 
variables. Each variable was examined for normal distribution and any positively-skewed 
variables were log transformed. Odds ratio (OR) (95% CI), predicting metabolic syndrome 
based on different indices for SO, were obtained from logistic regression models after 
controlling for potential covariates like gender and age. A P-value <0.05 was considered 
statistically significant in all analyses. All statistical results were based on two-sided tests. Data 
were analyzed using SPSS for Windows (Version 12.0; SPSS Inc.; Chicago, IL, USA). 
 
Results 
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The characteristics of the study population 
The characteristics of the all study subjects (20-88 years, n = 526) and young reference group 
(age 20-40 years, n=145) are detailed in Table 1. When men were compared with women, age, 
anthropometric indicators such as height, weight, BMI, visceral fat area (VFA), thigh muscle 
area (TMA), total lean body mass (LBM), ASM, ASM/height2 and SMI were all greater in men 
than women. Total body fat percentage and HDL-cholesterol were significant greater in women. 
There were no differences between men and women for the subcutaneous fat area (SFA) and 
LDL-cholesterol. 
 
Cut-off points for sarcopenia and obesity 
For men, the cut-off values for sarcopenia were 7.40 kg/m2 (ASM/height2) and 35.71% (SMI) 
defined as less than 2SD below the sex-specific normal mean for the young reference group. For 
women corresponding limits were 5.14 kg/m2 (ASM/height2) and 30.70% (SMI). The cut-off 
values for the lower two quintile for the distribution of ASM/height2 in our population were 
8.81 kg/m2 in men and 7.36 kg/m2 in women, respectively. To calculate the cut-off value for the 
residual method, we first established the model of predicted ASM using multiple linear 
regression analysis by adjusting for height and total fat mass. Sex-specific equations were 
predicted as ASM (kg) = -31.23 + 32.84 x height (m) + 0.24 × total fat mass (kg) for the men 
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and predicted as ASM (kg) = -19.10 + 21.65 x height (m) + 0.20 × total fat mass (kg) for the 
women. As a result, sex-specific cut-off points of the lower 20% of distribution of residuals 
were -1.87 for the men and -1.62 for the women. 
The cut-off values of obesity defined as the two highest quintiles of the total body fat 
percentage were 20.21% for the men and 31.71% for the women, respectively. These cut-off 
values for obesity in both men and women approximately corresponded to a BMI of 25 kg/m2 
according to a previous Korean study (17).  
 
Prevalence of sarcopenia 
The prevalence of sarcopenia in Korean men and women was estimated using four different 
methods (Table 2). When we used a cut-off point of 2 SD for ASM/height2 in the young 
reference group to define sarcopenia, the prevalence in Korean men and women aged more than 
60 years was 6.3% and 4.1%, respectively. When the cut-off point for sarcopenia was used as 
the lower two quintiles for ASM/height2, the prevalence of sarcopenia was much higher in both 
men and women (54.4% and 40.5%, respectively). Using the lowest 20th percentile of the 
residuals for ASM adjusted fat mass and height, the prevalence of sarcopenia in men and 
women of all ages was distributed evenly. When we used cutoff point of 2 SD for SMI in young 
reference group to define sarcopenia, the prevalence in the Korean men and women aged more 
 15 
than 60 years was 5.1% and 14.2%, respectively. 
 
Prevalence of sarcopenic obesity 
The prevalence of SO in Korean men and women was estimated using three different 
methods (Table 3). When we used a cut-off point of 2 SD for ASM/height2 plus the median of 
the total body fat percentage to define SO (Baumgartner’s method), the prevalence in Korean 
men and women aged more than 60 years in the KSOS was 1.3% and 0.8%. These results might 
be seen through the gender difference of age-related body compositional changes. Interestingly, 
the loss in appendicular skeletal muscle was greater in men than in women whereas intra-
abdominal fat accumulation in women was greater than in men with aging (Fig. 1). The 
prevalence of SO (as defined by Zoico et al.) was higher in both women and men when using 
Zoico’s method than by using other methods and was much higher especially in elderly men. 
When we use the new definition of SO (below -2SD of SMI plus two higher quintile of total 
body fat percentage), the prevalence of SO was 5.1% in men age 60 or older and 12.5% in 
women over 60 years of age. 
 
Comparison of SO defined by ASM/height2 index and SMI index 
Table 4 displays the characteristics of women classified with SO using two different methods. 
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Women subjects identified with SO using Zoico’s method were of similar age, BMI and 
metabolic parameters but significantly had other different body compositional parameters when 
compared with normal subjects. The SO group by the SMI index was older, fatter and had a 
greater number of metabolic risk factors than the normal group. The prevalence of metabolic 
syndrome was also higher in the SO group defined by the SMI index compared to the normal 
group (Fig 2). Although men had a lower occurrence of SO in the population, the characteristics 
of the two different SO groups in men mostly showed similar trends to those in the women 
participants. 
 
Odds ratio from logistic regression models predicting metabolic syndrome, based on different 
indices for SO 
Association between metabolic syndrome and ASM/height2 or SMI indices was shown in 
Table 5. A low SMI was associated with greater presence of metabolic syndrome among men 
and women age 40 and older. When SO was defined using ASM/height2 index, subjects with 
SO did not show a significantly increased risk of metabolic syndrome compared to normal 
subjects. However, using the SMI index, subjects with SO had 3 times the risk of metabolic 
syndrome (OR = 3.03, 95% confidence interval (CI) = 1.26-7.26) and subjects with non-
sarcopenic obesity had approximately 2 times the risk of metabolic syndrome (OR = 1.89, 95% 
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CI = 1.18-3.02) compared with normal subjects after adjustment for age and gender. 
 
Discussion 
The present study examined the prevalence of sarcopenia and SO in Korean men and women 
using different criteria. There was an apparent discrepancy of prevalence according to definition 
of sarcopenia. 
In the New Mexico Aging Process Study (NMAPS) and New Mexico Elderly Health Survey 
(NMEHS), it was first described by Baumgartner that the prevalence of SO in participants aged 
60 years and over was 3.0% of women and 4.4% of men, respectively. The prevalence increases 
from about 2% in participants 60 to 69 years of age to 10% in those over 80 years (7). The 
prevalence of SO in people aged 60 and older from KSOS were very low as based on 
Baumgartner’s definition. There could be several reasons for low prevalence in the present 
study. First, participants in our study were younger (mean age 66.1 years) and fatter (BMI 24.5 
kg/m2) than those in the Baumgartner’s study. Second, although the cut-off point of 
ASM/height2 of the young reference group are similar in men (18, 19), the cut-off point of 
ASM/height2 in women of the present study is 5% lower compared with previous study based 
on Caucasian population (20). Third, there was a relatively small difference of muscle mass 
between young and elderly Korean women. Especially, in Korean women, aging was well 
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associated with increased visceral fat accumulation rather than loss of skeletal muscle mass. 
An alternative definition of SO was subsequently suggested by Davison et al. (9) and Zoico et 
al. (8), who defined SO by combination the upper two quintiles of total fat percentage and lower 
two quintile of ASM/height2. When Zoico’s definition of SO was used, the prevalence in 
participants aged more than 60 years were 16.5% of women and 20.3% of men in the present 
study. Cut-off point (7.3 kg/m2) in ASM/height2 for women in the present study was higher than 
5.7 kg/m2 in Zoico’s study and 6.5 kg/m2 in Davison’s study. Although cut-off points (8.81 
kg/m2) in ASM/height2 for men in the present study was similar to that (9.11 kg/m2) in 
Davison’s study, Cut-off point (20.21%) in total body fat percentage for men was much lower 
than that (37.17%) in their study. It was maybe due to racial difference between Asian and 
Caucasian and relatively younger study population included in this study.  
ASM/height2 index is highly correlated with BMI (r = 0.74; P <0.001) as current criterion of 
obesity after adjusting for age and gender. Thus, this index primarily identified thin people as 
sarcopenic and could have a limitation of underestimating sarcopenia in overweight or obese 
subjects (16). To overcome this limitation, criteria for the sarcopenia proposed by Newman et al. 
are based on residuals (ASM adjusted for height and body mass) and the 20th percentile of the 
distribution of residuals was used as the cut-off point for sarcopenia. Newman et al. observed 
that 11.5% of men and 14.4% of obese (BMI >30kg/m2) women were defined as being 
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sarcopenic using the method of residual. Using the lower 20% of residual, the prevalence of 
sarcopenia in the present study was 22.3% for women and 15.4% for men age 60 and over. In 
addition, Janssen et al. proposed to convert absolute skeletal muscle mass (kg) to percentage 
skeletal muscle mass (SMI) (10). Using the cut-off points of 2SD below the mean for SMI for 
the young reference group, the prevalence of sarcopenia in people age 60 and over was 14.2% in 
women and 5.1% in men in the present study. These results were similar to the Janssen’s study 
where the prevalence for sarcopenia was 10% in women and 7% in men. Newman's or Janssen's 
definition can classify sarcopenia across the entire weight range of a person from thin to obese 
although there is no previous study describing the prevalence of SO using these definitions of 
sarcopenia. If residuals or SMI indices were adopted to identify individuals with sarcopenia, the 
prevalence of sarcopenia is expected to be higher especially in those who are obese or are 
women when compared to the ASM/height2 index. 
Despite many obese persons with low muscle mass in relation to body weight have disability 
and cardio-metabolic risk factors (10, 21), ASM/height2 index does not identify most obese 
people with sarcopenia. Thus, by using the SMI of 2SD below the value of the young reference 
group (Janssen’s index) and the upper two quintiles for the total body fat percentage (Zoico’s 
index), we present a new definition of SO. It may be enough to assume that subjects with SO 
may lead to more functional limitations as well as to more metabolic disorders than lean 
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sarcopenic or non-sarcopenic obese individuals (22). Only a few studies have evaluated the 
combined effect of sarcopenia and obesity on the physical function and metabolic abnormality. 
In NAMPS and NMEHS, Baumgartner et al. first described that there is an association between 
low relative muscle mass (ASM/height2) and functional impairment and disability (7, 20). 
Longitudinal results from the NMAPS showed that subjects with SO at the baseline were two or 
three times more likely to develop instrumental disability during the 8-year follow-up period 
than lean sarcopenic or non-SO individuals (23). However, Zoico et al. showed that high body 
fat and high BMI values rather than low muscle mass were associated with functional limitation. 
Furthermore, they reported that among the different indices of sarcopenia, only SMI predicted 
functional impairment and disability (8). The association between SO and metabolic 
abnormalities remains unknown. In the cross sectional analysis of the NMAPS, the prevalence 
of the metabolic syndrome was highest in the group of non-sarcopenic obese subjects followed 
by that of SO subjects and was the lowest in the sarcopenic non-obese subjects (22). In the 
present study, we found that subjects with SO had significant increase in the number of 
components of metabolic syndrome compared to normal subjects. Furthermore, SO was 
independently associated with metabolic syndrome (OR =3.03, 95% CI = 1.26-7.26) after an 
adjustment for age and gender. Considering the increased morbidity and mortality in patients 
with metabolic syndrome (24), these results might be a basis for the future study of health 
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outcome in patients with SO. 
It is likely that the loss of muscle mass and reduced strength (sarcopenia) causes reduced 
physical activity during aging. A reduction in muscle mass and physical activity levels decrease 
total energy expenditure which results in accumulation of fat mass especially visceral fat (2, 25). 
Along with visceral fat accumulation, loss of skeletal muscle which is the largest insulin-
responsive target tissue produces insulin resistance which promotes metabolic syndrome. 
Moreover, increase in visceral fat may lead to augmented secretion of pro-inflammatory 
adipokines that further promote insulin resistance as well as potentially a direct catabolic effect 
on muscles. Thus, a vicious circle between muscle loss and fat gain may lead to more 
sarcopenia and then to further fat gain and inflammation (22). Subjects with SO, defined by 
Zoico’s method, had similar BMI and metabolic parameters whereas subjects with SO defined 
by the new method using SMI index were associated with higher numbers of metabolic risk 
factors than normal subjects. Therefore, the definition of SO using SMI instead of ASM/height2 
might be more useful in examining the relationship between SO and metabolic syndrome in 
Korean adults.                                                                                                                                                                                                                                                                                                                                                                     
Our study has several limitations that must be considered. First, the cross-sectional nature of 
this study precluded our ability to identify any cause-effect relationships. Second, all 
participants in the present study were relatively healthy, well-functioning men and women and 
 22 
participants who had disabilities were excluded. Therefore, the present study may have 
underestimated the prevalence of SO. However, as the NMAPS cohort is composed of 
volunteers with relatively good health, we planned to explore the longitudinal effect of SO on 
metabolic abnormalities in conditions excluding other diseases in the present study. 
In summary, we examined the prevalence of sarcopenia and SO in Korean men and women 
and found considerable difference of prevalence for sarcopenia and SO according to which 
definition is used. We found a significant association between SMI quintile and metabolic 
syndrome. In addition, our study showed that subjects with SO were associated with a greater 
likelihood of metabolic syndrome. Considering that the Korean population has become more 
and more obese and has aged during the past few decades, the prevalence of SO and its impact 
on health outcomes are estimated to be rapidly increasing in the near future. Further research is 
needed to establish the definition, cause and consequences of SO. 
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Figure Legend 
Fig. 1. Relationship between age and appendicular skeletal muscle mass (A; men: r= -0.529, P <0.001, 
women: r= -0.165, P = 0.003) or visceral fat area (B; men: r= 0.128, P = 0.077, women: r= 0.558, P 
<0.001) in the study subjects 
Fig. 2. The difference of prevalence of the metabolic syndrome between subjects with sarcopenic obesity 
and normal subjects classified using two different definitions of sarcopenic obesity 
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Table 1. Clinical, anthropometric and metabolic characteristics of all study subjects (n = 526) and young 
reference subjects (n = 145) 
 All study subjects Young reference group 
 
Men  
(n=198) 
 Women (n=328) 
p 
Men  
(n=54) 
Women  
(n=91) 
p 
Age (years) 52.2 ± 14.4 51.2  ± 14.8 0.411  33.9 ± 5.2 31.2  ± 6.6 0.014 
Anthropometry 
Height (cm) 170.0 ± 6.8 156.7  ± 5.6 <0.001 175.1 ± 5.9 160.2  ± 5.2 <0.001 
Weight (kg) 73.1 ± 12.0 58.6  ± 9.2 <0.001 80.5 ± 13.9 57.6  ± 10.8 <0.001 
BMI (kg/m2) 25.2  ± 3.1 23.9  ± 3.7 <0.001 26.2  ± 3.1  22.4  ± 4.0  <0.001 
Waist circumference (cm) 89.6  ± 7.9 82.3  ± 8.6 <0.001 92.0  ± 9.1  80.0  ± 10.0  <0.001 
Metabolic parameters 
Systolic BP (mmHg) 125.9 ± 12.4 119.9  ± 13.9 <0.001 123.6 ± 12.2 110.2  ± 11.8 <0.001 
Diastolic BP (mmHg) 82.9 ± 9.8 77.3  ± 9.9 <0.001 81.2 ± 9.6 71.7  ± 8.2 <0.001 
Total cholesterol (mmol/L) 4.8 (4.1, 5.2) 4.8 (4.2, 5.4) 0.314 4.8 (4.2, 5.3) 4.3 (3.8, 4.7) 0.011 
Triglyceride (mmol/L) 1.5 (1.1, 2.2) 1.1 (0.8, 1.6) <0.001 1.7 (1.2, 3.0) 0.8 (0.6, 1.1) <0.001 
HDL cholesterol (mmol/L) 1.3 (1.0, 1.5) 1.5 (1.3, 1.7) <0.001 1.3 (1.1, 1.5) 1.5 (1.3, 1.8) <0.001 
LDL cholesterol (mmol/L) 2.6 (2.0, 3.0) 2.6 (2.2, 3.3) 0.059 2.5 (1.9, 3.1) 2.2 (1.9, 2.7) 0.179 
Fasting glucose (mmol/L) 5.5 ± 1.2 5.2 ± 0.8 0.001 5.2 ± 0.6 4.9 ± 0.4 <0.001 
Computed tomography (CT) 
VFA (cm2)  141.6  ± 59.8 103.1  ± 54.0 <0.001 130.1  ± 50.2 61.8  ± 33.4 <0.001 
SFA (cm2)  143.0  ± 69.9 192.2  ± 80.6 <0.001 183.9  ± 96.7 182.5  ± 80.0 0.926 
MTMA (cm2) 144.2  ± 33.4 97.3  ± 23.5 <0.001 162.5  ± 18.9 102.2  ± 20.0 <0.001 
VMR 0.9  ± 0.4 1.0  ± 0.5 0.117 0.8  ± 0.3 0.6  ± 0.3 <0.001 
Bioelectrical impedance analysis (BIA) 
Total body fat percentage (%)  21.3  ± 5.0 29.6  ± 6.2  <0.001 22.8  ± 5.6  28.3  ± 6.4  <0.001 
Total body fat mass (kg)  16.1  ± 6.0 18.1 ± 6.1  <0.001 19.0  ± 7.9  17.1 ± 6.6  0.0128 
Total lean body mass (kg) 54.7  ± 7.4  39.3  ± 4.2  <0.001 58.7  ± 7.4  39.3  ± 5.2  <0.001 
Dual Energy X-ray Absorptiometry (DXA) 
ASM (kg) 27.0  ± 4.4  18.5  ± 2.6 <0.001 29.9  ± 3.4  18.7  ± 3.2 <0.001 
ASM/height2 (kg/m2) 9.2  ± 1.3  7.6  ± 0.8  <0.001 9.8  ± 1.2  7.3  ± 1.1  <0.001 
SMI (%) 37.0  ± 3.2  31.8  ± 3.3  <0.001 43.6  ± 3.9  37.7  ± 3.5 <0.001 
Body mass index, BMI; Total fat area, TFA; Visceral fat area, VFA; Subcutaneous fat area, SFA; MTMA, Mid-
thigh muscle area; VMR, VFA/MTMA ratio; ASM, Appendicular skeletal muscle. 
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Table 2. Prevalence (%) of Sarcopenia using ASM/height2, SMI and residual methods 
 ASM/height2 ASM/height2 Residual SMI 
Indices of Sarcopenia below 2 SD 2 lower quintile 20th percentile Below 2 SD 
 (Baumgartner et al.) (Zoico et al.) (Newman et al.) (Janssen et al.) 
Men      
40-59 (n=72) 2.8 23.6 19.4 1.4 
≥ 60 (n=79) 6.3 54.4 15.4 5.1 
Women     
40-59 (n=120) 2.5 39.5 15.1 4.2 
≥ 60 (n=121) 4.1 40.5 22.3 14.2 
ASM ; appendicular skeletal muscle, SMI ; skeletal muscle index, SD ; standard deviation
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Table 3. Prevalence (%) of sarcopenic obesity using the different indices 
Indices of SO 
-2SD of ASM/height2  
plus Median of total  
body fat percentage  
(Baumgartner et al.) 
2 lower quintile of ASM/height2  
plus 2 higher quintile of total 
body fat percentage 
 (Zoico et al.)  
-2SD of SMI  
plus 2 higher quintile of total  
body fat percentage 
(New index of the present study) 
Men     
40-59 years (n=72) 2.8 9.7 1.4 
≥ 60 years (n=79) 1.3 20.3 5.1 
Women    
40-59 years (n=120) 0.8 11.8 3.3 
≥ 60 years (n=121) 0.8 16.5 12.5 
 ASM ; appendicular skeletal muscle, SMI ; skeletal muscle index, SD ; standard deviation, SO ; sarcopenic 
obesity 
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Table 4. Clinical, anthropometric and metabolic characteristics of sarcopenic obesity defined using different 
indices in women participants 
 
2 lower quintile of ASM/height2 
plus 2 higher quintile of total body 
fat percentage 
-2SD of SMI  
plus 2 higher quintile of total body 
fat percentage  
 
Normal 
(n=118) 
SO 
(n=31) 
p 
Normal  
(n=128) 
SO 
(n=19) 
p 
Age (years) 58.1 ± 9.4 61.0  ± 10.4 0.165 57.7 ± 9.2 63.5  ± 6.3 0.003 
Anthropometry 
Height (cm) 154.8 ± 4.7 155.2  ± 4.1 0.624 155.6 ± 5.6 153.2  ± 4.4 <0.001 
Weight (kg) 56.6 ± 5.6 57.0  ± 4.8 0.698 54.8 ± 5.9 68.9  ± 12.0 0.001 
BMI (kg/m2) 23.6  ± 2.1 23.6  ± 1.7 0.942 22.7  ± 2.4 29.3  ± 4.5 <0.001 
Waist circumference (cm) 80.5  ± 5.8 83.7  ± 5.1 0.004 79.3  ± 6.8 92.2  ± 8.9 <0.001 
Metabolic parameters 
Systolic BP (mmHg) 123.2 ± 13.0 123.1  ± 11.2 0.969 120.8 ± 12.5 126.2  ± 12.4 0.090 
Diastolic BP (mmHg) 79.0 ± 12.3 78.4  ± 8.1 0.758 78.5 ± 10.9 78.7  ± 6.0 0.902 
Total cholesterol (mmol/L) 5.0 (4.5, 5.5) 5.3 (4.7, 5.6) 0.232 4.9 (4.3, 5.4) 5.2 (4.5, 5.6) 0.466 
Triglyceride (mmol/L) 1.2 (0.9, 1.9) 1.5 (1.0, 1.7) 0.792 1.1 (0.8, 1.7) 1.4 (1.1, 1.7) 0.501 
HDL cholesterol (mmol/L) 1.4 (1.3, 1.8) 1.4 (1.2, 1.7) 0.284 1.5 (1.3, 1.8) 1.3 (1.2, 1.6) 0.135 
LDL cholesterol (mmol/L) 2.7 (2.3, 3.1) 3.1 (2.6, 3.5) 0.032 2.7 (2.3, 3.2) 3.0 (2.6, 3.5) 0.231 
Fasting glucose (mmol/L) 5.4 ± 0.8 5.3 ± 1.1 0.837 5.3 ± 0.8 5.6 ± 1.3 0.315 
Number of components of MetS 1.9 ± 1.4 2.0 ± 1.0 0.679 1.6 ± 1.3 2.5 ± 1.0 0.002 
Prevalence of MetS (%) 30.9 34.3 0.829 23.4 52.6 0.012 
Computed tomography (CT) 
VFA (cm2)  104.5  ± 46.2 125.1  ± 42.2 0.025 98.1  ± 45.9 170.1  ± 60.4 <0.001 
SFA (cm2)  163.7  ± 55.8 199.2  ± 65.0 0.007 158.0  ± 53.9 287.0  ± 113.8 <0.001 
MTMA (cm2) 104.5  ± 11.0 90.7  ± 9.3 <0.001 99.6  ± 12.1 98.5  ± 18.1 0.811 
VMR 1.0  ± 0.4 1.4  ± 0.4 <0.001 1.0  ± 0.4 1.7  ± 0.5 <0.001 
Bioelectrical impedance analysis (BIA) 
Total body fat percentage (%)  27.0  ± 5.0 32.7  ± 3.5  <0.001 26.5  ± 5.1  38.1  ± 4.4  <0.001 
Total body fat mass (kg)  15.8  ± 4.4 19.1 ± 3.0  <0.001 15.0  ± 4.1 27.0 ± 7.5  <0.001 
Total lean body mass (kg) 39.6  ± 3.3  36.9  ± 2.4  <0.001 38.6  ± 3.4  40.4  ± 5.3  0.053 
Dual Energy X-ray Absorptiometry (DXA) 
ASM (kg) 19.0  ± 1.7  16.4  ± 1.0 <0.001 18.1  ± 2.0  17.9  ± 2.6 0.611 
ASM/height2 (kg/m2) 7.9  ± 0.5  6.8  ± 0.3  <0.001 7.5  ± 0.7  7.6  ± 1.0  0.542 
SMI (%) 37.7  ± 2.6  32.1  ± 1.9  <0.001 37.2  ± 3.2  29.0  ± 0.9  <0.001 
Body mass index = BMI; Total fat area = TFA; Visceral fat area = VFA; Subcutaneous fat area = SFA; Mid-
thigh muscle area = MTMA; VFA/MTMA ratio = VMR; Appendicular skeletal muscle = ASM; SO = 
Sarcopenic obesity; MetS = metabolic syndrome.
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Table 5. Odds ratio from logistic regression models predicting metabolic syndrome, based on total body fat 
percentage quintile, ASM/height2 quintile, SMI quintile and sarcopenia/obesity grouping using two different 
indices 
Characteristics (n = 392) OR (95% CI)a 
ASM/height2 quintile 
 Women Men 
I    (< 6.86 kg/m2) (< 8.37 kg/m2) 0.20 (0.09-0.42) 
II   (6.87-7.36 kg/m2) (8.38-8.81 kg/m2) 0.18 (0.09-0.39) 
III   (7.37-7.72 kg/m2) (8.82-9.37 kg/m2) 0.43 (0.22-0.85) 
IV (7.73-8.30 kg/m2) (9.38-10.06 kg/m2) 0.68 (0.36-1.31) 
V (> 8.31 kg/m2) (> 10.07 kg/m2) 1.00  
Sarcopenia/obesity group (by Zoico’s method using ASM/height2 index)  
Normal body fat and muscle mass  1.00  
High body fat only 1.84 (1.08-3.15) 
Low muscle mass only 0.27  (0.14-0.54) 
SO 0.60 (0.30-1.21) 
SMI quintile  
 Women Men  
I  (< 32.40%) (< 39.84%) 3.44 (1.60-7.38) 
II (32.41-34.06%) (39.85-41.47%) 2.50 (1.16-5.37) 
III (34.07-35.78%) (41.48-43.10%) 2.53 (1.18-5.41) 
IV (35.79-37.87%) (43.11-45.29%) 1.83 (0.84-3.99) 
V (> 37.88%) (> 45.30%) 1.00  
Sarcopenia/obesity group (by New method using SMI index)  
Normal body fat and muscle mass  1.00  
High body fat only 1.89 (1.18-3.02) 
Low muscle mass only 6.05  (0.52-70.37) 
SO 3.03 (1.26-7.26) 
aAdjusted age and gender.  
CI = confidence interval. 
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Fig. 1. Relationship between age and appendicular skeletal muscle mass (A; men: r= -0.529, P <0.001, women: 
r= -0.165, P = 0.003) or visceral fat area (B; men: r= 0.128, P = 0.077, women: r= 0.558, P <0.001) in the study 
subjects. 
A.  
 
B. 
  
 
 33 
Fig. 2. The difference of prevalence of the metabolic syndrome between subjects with sarcopenic obesity and 
normal subjects classified using two different definitions of sarcopenic obesity 
 
 
 
P = 0.012 
! P < 0.001 
 
P = 0.829 
! P < 0.001 
 
